Matthew Manders - Cigna Corp President
CI Stock | USD 352.28 0.37 0.10% |
President
Mr. Matthew G. Manders was appointed as President Strategy Solutions of the Company effective December 1, 2018. He was President Government Individual Programs and Group Insurance of the Company effective effective November 3, 2017. He is President, Government Individual Programs and Group Insurance beginning February 2017 President, U.S. Markets from June 2014 until February 2017 President, Regional and Operations from November 2011 until June 2014 President, U.S. Service, Clinical and Specialty from January 2010 until November 2011 and President of Cigna HealthCare, Total Health, Productivity, Network Middle Market from June 2009 until January 2010. since 2021.
Age | 58 |
Tenure | 3 years |
Address | 900 Cottage Grove Road, Bloomfield, CT, United States, 06002 |
Phone | 860 226 6000 |
Web | https://www.cigna.com |
Cigna Corp Management Efficiency
The company has Return on Asset (ROA) of 0.0375 % which means that for every $100 of assets, it generated a profit of $0.0375. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.1179 %, which means that it produced $0.1179 on every 100 dollars invested by current stockholders. Cigna Corp's management efficiency ratios could be used to measure how well Cigna Corp manages its routine affairs as well as how well it operates its assets and liabilities. As of now, Cigna Corp's Return On Tangible Assets are increasing as compared to previous years. The Cigna Corp's current Return On Capital Employed is estimated to increase to 0.05, while Return On Equity is projected to decrease to 0.10. As of now, Cigna Corp's Return On Tangible Assets are increasing as compared to previous years. The Cigna Corp's current Intangibles To Total Assets is estimated to increase to 0.53, while Total Assets are projected to decrease to under 89 B.Similar Executives
Showing other executives | PRESIDENT Age | ||
Shawn Guertin | CVS Health Corp | 60 | |
Kevin Hourican | CVS Health Corp | 44 | |
Andrew Sussman | CVS Health Corp | 50 | |
Christopher Hunter | Humana Inc | 52 | |
Lisa Bisaccia | CVS Health Corp | 62 | |
Michelle Peluso | CVS Health Corp | 52 | |
Helena Foulkes | CVS Health Corp | 51 | |
J Joyner | CVS Health Corp | 51 | |
Christopher Kay | Humana Inc | 50 | |
Per Lofberg | CVS Health Corp | 67 | |
Regina Nethery | Humana Inc | N/A | |
Brian LeClaire | Humana Inc | 57 | |
Alan Wheatley | Humana Inc | 51 | |
Christopher Todoroff | Humana Inc | 54 | |
Derica Rice | CVS Health Corp | 53 | |
Eva Boratto | CVS Health Corp | 53 | |
George II | Humana Inc | 55 | |
MD MBA | Humana Inc | 50 | |
John III | Humana Inc | N/A | |
Tim McClain | Humana Inc | 64 | |
Susan Diamond | Humana Inc | 50 |
Management Performance
Return On Equity | 0.12 | ||||
Return On Asset | 0.0375 |
Cigna Corp Leadership Team
Elected by the shareholders, the Cigna Corp's board of directors comprises two types of representatives: Cigna Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cigna. The board's role is to monitor Cigna Corp's management team and ensure that shareholders' interests are well served. Cigna Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cigna Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
Nicole Jones, Executive Vice President, General Counsel | ||
Donna Zarcone, Independent Director | ||
Herbert Fritch, President of Cigna-Healthspring | ||
John Webb, President - Health Care | ||
Alexis Jones, Investor Principal | ||
Neesha Hathi, Independent Director | ||
David Guilmette, President - Global Employer Segment | ||
James Rogers, Independent Director | ||
Eric Foss, Independent Director | ||
William Zollars, Independent Director | ||
ALAN MUNEY, Executive Vice President Total Health & Network and Chief Medical Officer | ||
John Murabito, Executive Vice President - Human Resources, Chief Administrative Officer | ||
Christopher MBA, President Businesses | ||
Edwin Detrick, Vice President - Investor Relations | ||
Roman Martinez, Independent Director | ||
Ralph Giacobbe, Senior Relations | ||
Phil Austin, Head Markets | ||
Jane Henney, Independent Director | ||
Elder Granger, Independent Director | ||
Kimberly Ross, Independent Director | ||
Brian Evanko, Chief Financial Officer, Executive Vice President | ||
Matt Perlberg, Pharmacy President | ||
Kari Stevens, Chief VP | ||
David Cordani, CEO and President Director and Member of Executive Committee | ||
Terese CPA, Senior Officer | ||
Charles Berg, President - U.S. Government Business | ||
Mary Hoeltzel, Director | ||
Arjan Toor, Chief Operations | ||
Matthew Manders, President of U.S. Commercial Markets and Global Health Care Operations | ||
Timothy, Director | ||
Greg Allen, President of Tennessee Market | ||
Noelle Eder, Executive Vice President, Global Chief Information Officer | ||
Eric Palmer, Chief Financial Officer, Executive Vice President | ||
Dean Mirabella, President Markets | ||
Cynthia Ryan, Chief Human Resource Officer | ||
Brain Evanko, President Government Business | ||
Mark Boxer, Executive Vice President, Chief Information Officer | ||
Adam PharmD, President Services | ||
Jason Sadler, President of International Markets | ||
Timothy Wentworth, Chief Executive Officer - Evernorth | ||
Michael Phillips, President and General Manager - Midwest Market | ||
Lisa Bacus, Executive Vice President, Chief Marketing Officer, Chief Customer Officer | ||
Isaiah Harris, Independent Chairman of the Board | ||
William DeLaney, Independent Director | ||
Thomas McCarthy, CFO and Executive VP | ||
Kristen Lauria, Executive Vice President, Chief Marketing Officer | ||
Everett Neville, Executive Vice President, Strategy, Corporate Development and Solutions | ||
Paul Sanford, Executive Vice President - Operations | ||
John Partridge, Independent Director | ||
William McDowell, Vice President Investor Relations | ||
Michelle Gass, Independent Director | ||
Mark McClellan, Independent Director | ||
Kathleen Mazzarella, Independent Director | ||
Mary CPA, Senior Officer | ||
MICHAEL TRIPLETT, President - U.S. Commercial | ||
Steven Miller, Executive Vice President Chief Clinical Officer | ||
Mary Picerno, Chief Officer | ||
Eric Wiseman, Lead Independent Director | ||
CHRISTOPHER HOCEVAR, President Strategy, Segments and Solutions | ||
William Roper, Independent Director | ||
George Kurian, Independent Director |
Cigna Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cigna Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.12 | ||||
Return On Asset | 0.0375 | ||||
Profit Margin | 0.03 % | ||||
Operating Margin | 0.04 % | ||||
Current Valuation | 126.37 B | ||||
Shares Outstanding | 283.65 M | ||||
Shares Owned By Insiders | 1.50 % | ||||
Shares Owned By Institutions | 89.89 % | ||||
Number Of Shares Shorted | 5.57 M | ||||
Price To Earning | 13.93 X |
Pair Trading with Cigna Corp
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cigna Corp position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cigna Corp will appreciate offsetting losses from the drop in the long position's value.Moving together with Cigna Stock
0.65 | MRK | Merck Company Earnings Call Today | PairCorr |
Moving against Cigna Stock
0.67 | MCD | McDonalds Earnings Call This Week | PairCorr |
0.66 | CSCO | Cisco Systems Aggressive Push | PairCorr |
0.44 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
The ability to find closely correlated positions to Cigna Corp could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cigna Corp when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cigna Corp - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cigna Corp to buy it.
The correlation of Cigna Corp is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cigna Corp moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cigna Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cigna Corp can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cigna Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more detail on how to invest in Cigna Stock please use our How to Invest in Cigna Corp guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Complementary Tools for Cigna Stock analysis
When running Cigna Corp's price analysis, check to measure Cigna Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cigna Corp is operating at the current time. Most of Cigna Corp's value examination focuses on studying past and present price action to predict the probability of Cigna Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cigna Corp's price. Additionally, you may evaluate how the addition of Cigna Corp to your portfolios can decrease your overall portfolio volatility.
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Stocks Directory Find actively traded stocks across global markets | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing |
Is Cigna Corp's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cigna Corp. If investors know Cigna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cigna Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.10) | Dividend Share 4.92 | Earnings Share 17.39 | Revenue Per Share 664.145 | Quarterly Revenue Growth 0.116 |
The market value of Cigna Corp is measured differently than its book value, which is the value of Cigna that is recorded on the company's balance sheet. Investors also form their own opinion of Cigna Corp's value that differs from its market value or its book value, called intrinsic value, which is Cigna Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cigna Corp's market value can be influenced by many factors that don't directly affect Cigna Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cigna Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cigna Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cigna Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.